Rotavirus vaccines

Scand J Infect Dis. 2008;40(9):691-5. doi: 10.1080/00365540802040570.


Two live attenuated oral rotavirus vaccines were licensed in 2006 for prevention of severe acute gastroenteritis in children: Rotarix (GSK), a human rotavirus vaccine with G1P[8] serotype characteristics and RotaTeq (Merck), a bovine-human reassortant vaccine expressing human G1-4 and P[8] antigens. In prelicensure trials both vaccines showed high efficacy against severe RV gastroenteritis, low reactogenicity and no increased risk for intussusception (IS) (Ruiz-Palacios et al., 2006; Vesikari et al., 2006). Both vaccines have now been distributed in millions of doses. Post-marketing data have not shown any gross signal for IS with either vaccine, but further data and analyses are required for final conclusion on safety of these vaccines.

Publication types

  • Review

MeSH terms

  • Animals
  • Cattle
  • Clinical Trials as Topic
  • Gastroenteritis / prevention & control*
  • Humans
  • Infant
  • Rotavirus Infections / prevention & control*
  • Rotavirus Vaccines* / administration & dosage
  • Rotavirus Vaccines* / adverse effects
  • Rotavirus Vaccines* / therapeutic use
  • Rotavirus* / classification
  • Rotavirus* / genetics
  • Rotavirus* / immunology
  • Treatment Outcome
  • Vaccination
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / therapeutic use


  • RIX4414 vaccine
  • RotaTeq
  • Rotavirus Vaccines
  • Vaccines, Attenuated
  • rhesus rotavirus vaccine